A
Avalyn Pharma
Advancing Therapies For the treatment of Idiopathic Pulmonary Fibrosis
About Avalyn Pharma
Avalyn Pharma is a clinical-stage biopharmaceutical company that specializes in developing inhaled therapies for rare respiratory diseases. The company operates in the healthcare and pharmaceutical market, specifically focusing on rare lung diseases such as idiopathic pulmonary fibrosis and other interstitial lung diseases. These are conditions that severely affect a patient's quality of life, and Avalyn aims to provide targeted therapies to improve patient outcomes.
Read full description
Their primary product in development is AP01, an inhaled formulation of pirfenidone. This product is currently in the Phase 2b stage of clinical trials, meaning it is being tested for effectiveness and side effects in larger groups of patients. If successful, AP01 could provide a new treatment option for pulmonary fibrosis, a disease that currently has limited treatment options.
Avalyn's business model revolves around the research, development, and eventual commercialization of these inhaled therapies. They aim to create inhaled versions of already approved medications, which could potentially offer a more effective and convenient treatment method for patients. The company generates revenue through the successful development and subsequent sale of these therapies to healthcare providers.
In summary, Avalyn Pharma is a pioneering biopharmaceutical company, developing innovative inhaled therapies for rare lung diseases, with a primary focus on improving patient quality of life.
At a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Cambridge, United States
- Employees
- 57
- Open positions
- 1
- Dealroom signal
- 49.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Pulmonary, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Avalyn Pharma.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Apr 2026 | $300M | $1.1B | Undisclosed | ↗ |
| SERIES DOther financing | Jul 2025 | $100M | $875M | Norwest Venture Partners · TPG Biotech · F-Prime · Eventide Asset Management | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Avalyn Pharma is 6.2K monthly website visits, down 12.7% over the last three months. Avalyn Pharma's team grew 1.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
TPG Biotech
Novo Holdings
Andera Partners
Eight Roads Ventures
Norwest Venture Partners
Pivotal Life Sciences
RiverVest Venture Partners
F-Prime
Series B and later14 investors entered at this stage
SR One
Eventide Asset Management
Wellington Management
Perceptive Advisors
Piper Sandler
Surveyor Capital
Rock Springs Capital
Vida Ventures
T. Rowe Price
Catalio Capital Management
Suvretta Capital Management- PFPerceptive Xontogeny Venture Fund
Pivotal BioVenture Partners- HMHamilton Square Partners Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Avalyn Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Avalyn Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.